Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
---|---|---|---|---|---|---|
Filed 2017-02-03 Tx date 2017-01-27 |
$NVLN
Novelion Therapeutics Inc. |
Smith, Sandford
4 - Director of Issuer
Direct Ownership
|
Restricted Stock Unit
36 - Conversion or exchange
|
-456 vol |
||
Filed 2017-02-03 Tx date 2017-01-27 |
$NVLN
Novelion Therapeutics Inc. |
Smith, Sandford
4 - Director of Issuer
Direct Ownership
|
Restricted Stock Unit
36 - Conversion or exchange
|
-456 vol |
||
Filed 2017-02-03 Tx date 2017-01-27 |
$NVLN
Novelion Therapeutics Inc. |
Smith, Sandford
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,388.24
-148 vol $9.38 each |
||
Filed 2017-02-03 Tx date 2017-01-27 |
$NVLN
Novelion Therapeutics Inc. |
Smith, Sandford
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,388.24
-148 vol $9.38 each |
||
Filed 2017-01-31 Tx date 2017-01-27 |
$NVLN
Novelion Therapeutics Inc. |
Smith, Sandford
4 - Director of Issuer
Direct Ownership
|
Restricted Stock Unit
36 - Conversion or exchange
|
-456 vol |
1,367 | |
Filed 2017-01-31 Tx date 2017-01-27 |
$NVLN
Novelion Therapeutics Inc. |
Smith, Sandford
4 - Director of Issuer
Direct Ownership
|
Common Shares
36 - Conversion or exchange
|
+456 vol |
1,048 | |
Filed 2017-01-31 Tx date 2017-01-27 |
$NVLN
Novelion Therapeutics Inc. |
Smith, Sandford
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,388.24
-148 vol $9.38 each |
900 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Smith, Sandford
4 - Director of Issuer
Direct Ownership
|
Restricted Stock Unit
37 - Stock split or consolidation
|
-7,292 vol |
1,823 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Smith, Sandford
4 - Director of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
-2,371 vol |
592 | |
Filed 2016-12-27 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Smith, Sandford
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-27 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Smith, Sandford
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+9,600 vol |
9,600 | |
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Smith, Sandford
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Smith, Sandford
4 - Director of Issuer
Direct Ownership
|
Restricted Stock Unit
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
+9,115 vol |
9,115 | |
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Smith, Sandford
4 - Director of Issuer
Direct Ownership
|
Restricted Stock Unit
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Smith, Sandford
4 - Director of Issuer
Direct Ownership
|
Common Shares
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
+2,963 vol |
2,963 |